Nuvation Bio Inc. (NUVB) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 7 Buy, 2 Hold.
The consensus price target is $12.40 (low: $10.00, high: $17.00), representing an upside of 155.7% from the current price $4.85.
Analysts estimate Earnings Per Share (EPS) of $-2.12 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.11 vs est $-2.12 (beat +0.5%). 2025: actual $-0.60 vs est $-0.59 (missed -2.3%). Analyst accuracy: 99%.
NUVB Stock — 12-Month Price Forecast
$12.40
▲ +155.67% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Nuvation Bio Inc., the average price target is $12.40, with a high forecast of $17.00, and a low forecast of $10.00.
The average price target represents a +155.67% change from the last price of $4.85.
Highest Price Target
$17.00
Average Price Target
$12.40
Lowest Price Target
$10.00
NUVB Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Nuvation Bio Inc. in the past 3 months
EPS Estimates — NUVB
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.11
vs Est –$2.12
▲ 0.5% off
2025
Actual –$0.60
vs Est –$0.59
▼ 2.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NUVB
61%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.008B
vs Est $0.002B
▲ 72.4% off
2025
Actual $0.063B
vs Est $0.059B
▲ 6.4% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
